Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Karyopharm Therapeutics (KPTI) Wild Ride Occurring as M&A Speculation Proved Wrong Amid Executive Departure - RBC
February 22, 2022 12:40 PM ESTRBC Capital analyst Brian Abrahams weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) amid the recent turbulence in the stock, including the 20% up move on Friday on the conference cancellation, which triggered M&A speculation, and today's 31% downdraft on the departure of CMO Dr. Jatin... More
Pre-Open Stock Movers 02/22: (MTOR) (VEV) (HMHC) Higher; (FIXX) (KPTI) (YNDX) Lower (more...)
February 22, 2022 9:20 AM ESTPre-Open Stock Movers:
Meritor, Inc. (NYSE: MTOR) 44.5% HIGHER; Cummins Inc. (NYSE:... More
Karyopharm Therapeutics (KPTI) CMO has stepped down to pursue other professional opportunities
February 22, 2022 7:12 AM EST(Updated - February 22, 2022 7:23 AM EST)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity.
"As accomplished leaders with proven track... More
Karyopharm Therapeutics (KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg
February 18, 2022 10:15 AM ESTKaryopharm Therapeutics (NASDAQ: KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg, Citing Email
... MoreUPDATE: Karyopharm Therapeutics (KPTI) shares gain 13% in early trading, bucking market weakness
February 18, 2022 9:37 AM EST(Updated - February 18, 2022 9:41 AM EST)
Karyopharm Therapeutics (NASDAQ: KPTI) shares gain 13% in early trading, bucking market weakness.
gains tied to news the company canceled from today's fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. This was said... More